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RUNNING TITLE: M. HYOPNEUMONIAE VARIABILITY AND CLASSIFICATION 23 
Summary 24 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the etiologic agent of enzootic pneumonia in 25 
swine, a prevalent chronic respiratory disease worldwide. Mycoplasma hyopneumoniae is a small, 26 
self-replicating microorganism that possesses several characteristics allowing for limited 27 
biosynthetic abilities, resulting in the fastidious, host-specific growth, and unique pathogenic 28 
properties of this microorganism. Variation across several isolates of M. hyopneumoniae has been 29 
described at antigenic, proteomic, transcriptomic, pathogenic, and genomic levels. The 30 
microorganism possesses a minimal number of genes that regulate the transcription process. Post-31 
translational modifications (PTM) occur frequently in a wide range of functional proteins. The 32 
PTM by which M. hyopneumoniae regulates its surface topography could play key roles in cell 33 
adhesion, evasion, and/or modulation of the host immune system. 34 
The clinical outcome of M. hyopneumoniae infections is determined by different factors, such as 35 
housing conditions, management practices, co-infections, and also by virulence differences among 36 
M. hyopneumoniae isolates. Factors contributing to adherence and colonization as well as the 37 
capacity to modulate the inflammatory and immune responses might be crucial.  38 
Different components of the cell membrane (i.e. proteins, glycoproteins and lipoproteins) may 39 
serve as adhesins and/or be toxic for the respiratory tract cells. Mechanisms leading to virulence 40 
are complex and more research is needed to identify markers for virulence.  41 
The utilization of typing methods, and complete or partial-gene sequencing for M. hyopneumoniae 42 
characterization has increased in diagnostic laboratories as control and elimination strategies for 43 
this microorganism are attempted worldwide. A commonly employed molecular typing method 44 
for M. hyopneumoniae is Multiple-Locus Variable number tandem repeat Analysis (MLVA). The 45 
agreement of a shared terminology and classification for the various techniques, specifically 46 
MLVA, has not been described, which makes inferences across the literature not suitable. 47 
Therefore, molecular trends for M. hyopneumoniae have been outlined and a common terminology 48 
and classification based on VNTR types has been proposed.  49 
 50 
Keywords: genomic classification, Mycoplasma hyopneumoniae, terminology, VNTR, 51 
variability  52 
1. Introduction 53 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the etiologic agent of enzootic pneumonia 54 
(EP) in swine (Mare & Switzer, 1965; Goodwin et al., 1965), a worldwide prevalent, chronic 55 
respiratory disease (Maes et al., 2018). Similar to other mycoplasmas, M. hyopneumoniae is a 56 
small, self-replicating microorganism that possesses several characteristics allowing for limited 57 
biosynthetic abilities, resulting in the fastidious, host-specific growth, and unique pathogenic 58 
properties of this microorganism (Razin et al., 1998). The pathogenesis of M. hyopneumoniae is 59 
complex and not yet fully elucidated. It is perceived that the level of colonization and initial 60 
development of EP depend on the ability for M. hyopneumoniae to adhere to ciliated epithelium 61 
within respiratory airways, which is mediated through receptor-ligand interactions and surface 62 
adhesion proteins (Ross, 1999; Minion et al., 2000). Once adherence occurs, the epithelium 63 
becomes deciliated and bronchial epithelial and goblet cells are lost, leading to the impairment of 64 
the mucociliary tract apparatus and the invasion of secondary respiratory pathogens to induce 65 
disease (DeBey et al., 1992; Thacker & Minion, 2012). The development of EP is assumed to 66 
occur from antigenic variation (Wise, 1993; de Castro et al., 2006), influx of pro-inflammatory 67 
cytokines to the site of infection due to alteration in the host immune response (Thacker et al., 68 
2000; Rodriguez et al., 2004), and potentially the formation of biofilms in the airways (Raymond 69 
et al., 2018). Clinical signs suggestive of M. hyopneumoniae infection consist of dry cough, 70 
labored breathing, and reduced growth rate (Thacker and Minion, 2012), which usually occur after 71 
six to eight weeks post-exposure (Sibila et al., 2009). Economical losses result from the clinical 72 
manifestations of EP, and the increased costs of prevention and eradication, that are implemented 73 
to combat further disease and occurrence of secondary bacterial pathogens infections (Pointon et 74 
al., 1985; Straw et al., 1990; Maes et al., 2018). Control strategies for M. hyopneumoniae, including 75 
antimicrobials, vaccines, and management practices, have been employed to reduce the economic 76 
losses derived from the clinical manifestations of EP (Pieters and Fano, 2016; Maes et al., 2018; 77 
Garza-Moreno et al., 2018).  78 
Several laboratory techniques have been utilized to characterize M. hyopneumoniae and have 79 
shown differences at antigenic, proteomic, transcriptomic, pathogenic, and genomic levels 80 
(Assunçao et al., 2005; Calus et al., 2007; Minion et al., 2004). Understanding M. hyopneumoniae 81 
at the molecular level would eventually aid in the advancement of disease control strategies. 82 
However, discrepancies regarding the molecular characterization of M. hyopneumoniae are present 83 
across the literature, and inferences based on such information can be challenging to agree upon. 84 
Common methods for genomic classification and interpretation would provide clarity on disease 85 
and outbreak investigations for this microorganism. Therefore, this review article aims to 86 
summarize published information on M. hyopneumoniae variability at the antigenic, proteomic, 87 
transcriptomic, pathogenic, and genomic levels, while highlighting methods employed for the 88 
characterization and classification at the genomic level, proposing commonality among 89 
investigations.  90 
2. Mycoplasma hyopneumoniae variability 91 
Mycoplasma species have been suggested to have phylogenetically evolved from gram-positive, 92 
walled eubacteria, allowing for unique, taxonomic characteristics (Maniloff, 1983; Razin, 1985). 93 
Studies have demonstrated the ability of M. hyopneumoniae to undergo phenotypic switching, 94 
antigenic variation and proteome alterations that may contribute to the versatility and variations 95 
between host-pathogen interactions (Minion et al., 2004; Assunçao et al., 2005; Calus et al., 2007). 96 
Variability has been demonstrated across several M. hyopneumoniae strains and isolates at the 97 
antigenic, proteomic, transcriptomic, pathogenic, and genomic level. For the purpose of this study, 98 
the difference between a bacterial strain and an isolate is that the former has been characterized 99 
(classified and/or identified) and the latter has been obtained from single colony cloning using 100 
pure culture.  101 
2.1. Antigenic variability 102 
Antigenic variability is described as the ability of a microorganism to alter its surface components 103 
(i.e. flagella, microvilli and/or membrane proteins, among others), causing differences in the host 104 
immune response against those structures (Razin et al., 1998). Among M. hyopneumoniae strains, 105 
antigenic variability, has been evaluated in several studies using different serologic and proteomic 106 
assays, such as immunoblotting and two-dimensional gel electrophoresis (Ro & Roos, 1983; 107 
Scarman et al., 1997; Assunçao et al., 2005). Techniques used, antigenic proteins identified, and 108 
the most relevant findings of each study are summarized in Table 1.   109 
Mycoplasma hyopneumoniae has a relatively small number of proteins with identified antigenic 110 
properties (Table 1), including cytosolic (i.e. P36), membrane (i.e. P44, P46, P50, P65, P70, P74 111 
and P76, among others) or adhesion proteins (i.e. P97). The cytosolic protein P36, named lactate 112 
dehydrogenase (LDH; Hadimann et al., 1993), was detected in 13 M. hyopneumoniae field strains 113 
from Switzerland, Hungary, France and Canada (Stipkovits et al., 1991). In contrast, a subsequent 114 
report concluded that this protein was not detected in the 18 studied M. hyopneumoniae field strains 115 
from Spain (Assunção et al., 2005). However, it remains unknown whether this lack of detection 116 
is the result of a true absence or is derived from the lack of expression due to unfavorable culture 117 
conditions, as previously described for other bacteria such as Escherichia coli (Jang et al., 2001), 118 
or a detection failure due to substantial sequence variability between different M. hyopneumoniae 119 
strains.  120 
Information regarding membrane protein immunoreactivity is scarce. For example, P46 was 121 
identified in all tested strains (Assunção et al., 2005) and it was considered useful for the 122 
development of an ELISA test for M. hyopneumoniae antibody monitoring (Okada et al., 2005). 123 
Another membrane protein (P74) with well-known antigenic properties is currently used as antigen 124 
for a commercial ELISA test to detect antibodies against the pathogen (Bereiter and Young, 1990). 125 
In addition, P44, P50, P65 and P70 are also membrane proteins that confer different proteolytic 126 
epitope maps (Wise & Kim, 1987a, 1987b). Similarly, antigenic variability of adhesins such as 127 
P97, involved in the adherence of M. hyopneumoniae to the cilia, was detected in all studied strains 128 
(Zhang et al., 1995; Assunção et al., 2005).  129 
Differences of antigenic profiles has been related to the variation in the size (Assunção et al., 2005;  130 
Wise & Kim, 1987b; Zhang et al., 1995), the expression of the proteins (Rosengarten & Yogev, 131 
1996; Razin et al., 1998), and adaptation mechanisms of M. hyopneumoniae against environmental 132 
changes, e.g. culture passages (Razin et al., 1998; Assunção et al., 2005). Such variability has been 133 
proposed as a pathogenic mechanism to evade the porcine immune response (Zhang et al., 1995). 134 
Although Mycoplasma hyopneumoniae antigenic diversity has been shown, a close relationship of 135 
antigenic profiles between different strains has also been described (Ro and Ross, 1983). In fact, 136 
comparable antigenic profiles (immunoreactivity against proteins of molecular weight from 36 to 137 
200 kDa) were detected in different M. hyopneumoniae strains from Australia, the United 138 
Kingdom and the United States using sodium dodecyl sulfate polyacrylamide gel electrophoresis 139 
(SDS-PAGE) as well as immunoblotting techniques (Scarman et al., 1997). This information 140 
suggests that limited antigenic variability among several M. hyopneumoniae strains obtained from 141 
different geographical locations can also occur, proposing the presence of conserved antigens 142 
related to the survival of the species (Scarman et al., 1997). 143 
Additionally, the existence of cross-reactive antigens between M. hyopneumoniae and other swine 144 
mycoplasmas like M. hyorhinis, M. hyosynoviae and M. flocculare has been documented (Table 145 
1). The closest antigenic relationship was described between M. hyopneumoniae and M. flocculare 146 
strains (Ro & Ross, 1983; Petersen et al., 2016). In fact, one recent study indicated that only 3 147 
(mhp182, mhp638 and mhp684) out of 39 tested M. hyopneumoniae proteins were exclusively 148 
present in M. hyopneumoniae and did not cross-react with M. hyorhinis, M. hyosynoviae and M. 149 
flocculare (Petersen et al., 2016). Similarly, a 43 kDA protein was identified as reactive with M. 150 
hyopneumoniae but not with M. flocculare or M. hyorhinis (Scarman et al., 1997).  151 
The M. hyopneumoniae antigenic variability described in the previously mentioned studies may 152 
have several implications. Although the mechanisms of M. hyopneumoniae pathogenesis have not 153 
been fully elucidated, surface protein variation might play a crucial role in M. hyopneumoniae 154 
adhesion to the ciliated epithelium (Wise & Kim, 1987) and to evade the host immune system 155 
(Maes et al., 2018). Indeed, antigenic differences could modify the ability to induce immune 156 
responses among M. hyopneumoniae strains as it has been observed under experimental (Vicca et 157 
al., 2002; Strait, 2003) and natural conditions (Ameri et al., 2006). Likewise, it is still unclear 158 
whether putative antigenic variations may imply differences in the antibody profiles generated by 159 
field strains when compared to those used in bacterins (Villarreal et al., 2012). Furthermore, the 160 
cross-reactivity detected between M. hyopneumoniae and other swine mycoplasmas may interfere 161 
with the results of serological diagnostic methods (Rosengarten and Yogev, 1996; Assunçao et al., 162 
2005; Petersen et al., 2016). Therefore, these findings indicate the need to identify conserved M. 163 
hyopneumoniae antigens as targets to develop new vaccines against this bacterium, as well as 164 
highly accurate serological diagnostic tests.  165 
2.2. Proteomic and transcriptomic variability 166 
Under adverse conditions, M. hyopneumoniae, like other bacteria, launches “stress responses” that 167 
improve its chances of a successful adaptation to the challenges posed by unfavorable 168 
environments. Such adaptation is reflected in protein diversification by means of different 169 
mechanisms, thus allowing the microorganism to survive, colonize, and cause disease.  170 
One mechanism of protein diversification is gene expression regulation. Several transcriptomic 171 
studies have aimed to identify differences in gene expression, under different environmental 172 
conditions, such as heat shock (Madsen et al., 2006), iron deprivation (Madsen et al., 2006), 173 
oxidative stress (Schafer et al., 2007), and norepinephrine exposure (Oneal et al., 2008). Most of 174 
the referenced studies agree that, in face of adverse conditions, an increase in the regulation of 175 
metabolic related genes occurs, while there is an expression decrease in transcription and 176 
translation of related genes.  177 
Using different approaches, high variability of total proteins among field and reference M. 178 
hyopneumoniae strains has been observed (Assunção et al., 2005; Calus et al., 2007; Pinto et al., 179 
2007; Pinto et al., 2009). In fact, the analysis of M. hyopneumoniae field isolates, obtained from 180 
several herds located in the same or different countries with various degrees of virulence, 181 
demonstrated high protein variability without relation to isolate source (Assunção et al., 2005; 182 
Calus et al., 2007). High protein heterogeneity has been already observed between pathogenic (i.e. 183 
232 and 7448) and non-pathogenic (i.e. J) M. hyopneumoniae strains (Pinto et al., 2007; Pinto et 184 
al., 2009; Li et al., 2009). Moreover, Paes et al. (2017) compared the secretomes of M. 185 
hyopneumoniae strain 7448 and the commensal M. flocculare. They identified that a higher 186 
number of proteins were secreted by the virulent M. hyopneumoniae strain 7448 (62) compared to 187 
M. flocculare (26). Overall, 15 virulence-related proteins were identified in M. hyopneumoniae 188 
strain 7448 and only four in M. flocculare, of which two proteins were shared with M. 189 
hyopneumoniae.  However, evidence suggests that protein variability is not necessarily related to 190 
virulence (Calus et al., 2007; Pinto et al., 2007; Pinto et al., 2009). Pinto et al. (2009) showed 191 
differential expression in approximately one-third of the proteome between two strains of similar 192 
virulence. Furthermore, an overexpression of proteins related to heat-shock and oxidative stress 193 
responses was observed in the pathogenic M. hyopneumoniae strains 7448 and 7422, compared to 194 
the non-pathogenic M. hyopneumoniae strain J.  195 
Mycoplasma hyopneumoniae possesses a minimal number of genes that regulate the transcription 196 
process (Vasconcelos et al., 2005), thus, the regulation of post-translational processes is relevant 197 
for this pathogen. Post-translational modifications (PTM) occur frequently in a wide range of 198 
functional proteins of M. hyopneumoniae (Tacchi et al., 2016). Endoproteolytic cleavage has been 199 
identified in cell surface proteins as lipoproteins, multitasking proteins (Tacchi et al., 2016) and 200 
P97/P102 adhesins (Bogema et al., 2011; Bogema et al., 2012; Djordjevic et al., 2004; Deutscher 201 
et al., 2010, Deutscher et al., 2012; Raymond et al., 2013; Raymond et al., 2015; Seymour et al., 202 
2012; Tacchi et al., 2014; Wilton et al., 2009). The PTM by which M. hyopneumoniae regulates 203 
its surface topography could play key roles in cell adhesion and evasion and/or modulation of the 204 
host immune system. 205 
Finally, secreted proteins from both, swine respiratory cells and M. hyopneumoniae, play 206 
important roles between the host-pathogen interaction. Mycoplasma hyopneumoniae strain 7448 207 
secretes higher number of adhesins and other proteins with known function than M. 208 
hyopneumoniae J strain and M. flocculare (Leal Zimmer et al., 2018; Paes et al., 2017), which may 209 
be related to bacterial pathogenicity. On the other hand, swine tracheal cells showed different 210 
secretion profiles in response to the infection with M. hyopneumoniae strains or with M. flocculare 211 
(Leal Zimmer et al., 2018). Some proteins secreted in response to cell injury and death, as Damage-212 
associated molecular patterns (DAMPs) proteins and extracellular proteasome proteins, have been 213 
detected only in swine cells infected with the M. hyopneumoniae 7448 (Leal Zimmer et al., 2018). 214 
These results suggest differences in the secretome composition from M. hyopneumoniae according 215 
to the virulence of the strain. 216 
2.3. Pathogenic variability 217 
The pathogenicity of an organism refers to its ability to cause disease or lesions to the host. 218 
Commensals and opportunistic pathogens lack this inherent ability. Virulence refers to the degree 219 
of disease or lesion severity caused by the organism. 220 
2.3.1. Differences in virulence 221 
The clinical outcome of M. hyopneumoniae infections is determined by different factors such as 222 
housing conditions, management practices, infections with other pathogens, and also by 223 
differences among M. hyopneumoniae strains.  224 
Previous studies have shown that M. hyopneumoniae field isolates may induce different levels of 225 
disease and lesions upon infection. The first and most extensive study was conducted by Vicca et 226 
al. (2003) in which the virulence of six field isolates of M. hyopneumoniae was compared using 227 
challenge infections in conventional pigs followed by necropsy four weeks later (commonly 228 
accepted as the standard infection model). The isolates were classified as highly, moderately, or 229 
low virulent based on severity of clinical signs and macroscopic and microscopic lung lesions 230 
produced. The virulence of some of these M. hyopneumoniae isolates was confirmed in subsequent 231 
studies (Meyns et al., 2004; Villarreal, 2009; 2011). Woolley et al (2012) also observed differences 232 
between two Australian M. hyopneumoniae field isolates (i.e. Hillcrest and Beaufort), with the first 233 
one being superior to experimentally induce more severe coughing and pneumonic lesions than 234 
the second isolate.  235 
Although M. hyopneumoniae is primarily a respiratory pathogen, it has also been isolated (Le 236 
Carrou et al., 2006; Marois et al., 2007; Marchioro et al., 2014) or detected by PCR (Woolley et 237 
al., 2012) in liver, spleen, and kidneys of experimentally infected and contact pigs. However, this 238 
spread within the body appears to be transient and is likely not involved in the development of 239 
disease (Marois et al., 2007; Woolley et al., 2012). Woolley et al. (2012) could only detect the 240 
highly virulent isolate in internal organs and not the low virulent isolate. Interaction with surface 241 
accessible actin on the epithelial cells and the causation of cytoskeletal rearrangements would 242 
allow this microorganism to be phagocytosed. It has been hypothesized that M. hyopneumoniae 243 
can survive within and escape the phagolysosome and reside within the cytoplasm (Tacchi et al., 244 
2016). Therefore, it can not only evade the immune system but could disseminate to internal 245 
organism and persist within the host without causing disease. Recent work by Raymond et al. 246 
(2018) showed that approximately 8% of M. hyopneumoniae cells reside intracellularly, which 247 
demonstrates the need to further explore this topic.  248 
2.3.2. Virulence factors 249 
Little is known about the mechanisms involved in these differences and the virulence factors of 250 
M. hyopneumoniae. It is also unclear why in certain pigs, M. hyopneumoniae might remain in the 251 
respiratory tract without causing clinical signs, or which factors are involved in progressing from 252 
presence of the pathogen to infection. Factors contributing to adherence and colonization, as well 253 
as the capacity to modulate the inflammatory and immune response might play a role. Meyns et 254 
al. (2007) showed that the difference between the highly and low virulent isolates was associated 255 
with a faster in vitro growth, a higher capacity to multiply in the lungs and the induction of a more 256 
severe inflammation process (e.g. higher TNF-alpha and IL-1β concentration in BAL fluid) by the 257 
highly virulent isolate. Woolley et al. (2012) also detected significantly higher levels of IL-1β and 258 
IL-6 in BAL fluid in pigs challenged with a highly virulent strain. A faster in vitro multiplication 259 
of a highly virulent isolate during the logarithmic phase was confirmed by Calus et al. (2010), 260 
suggesting a higher capacity to multiply in the lungs. In contrast, García-Morante et al. (2018) 261 
described the fastest growing strain to be M. hyopneumoniae strain J using color changing units.   262 
Villarreal et al. (2011) demonstrated that contrary to a highly virulent strain, a low virulent strain 263 
required more than 4 weeks post-infection to reach maximum infection levels and clinical signs.  264 
Different components of the cell membrane (i.e. proteins, glycoproteins and lipoproteins) may 265 
serve as adhesins and/or be toxic for the respiratory tract cells. Some of the molecules are post-266 
translationally processed and cleaved. It is possible that highly virulent strains have a different cell 267 
surface composition and/or a different proteolytic processing. It has been proposed that a minimum 268 
of eight repeat region 1 (RR1) units located at the carboxy terminus of the mhp183 gene as the 269 
cilium- and antibody-binding sites of P97, is required for cilium binding (Minion et al., 2000). 270 
Whilst the amino acid sequence of P97 is highly conserved amongst M. hyopneumoniae strains 271 
(Wilton et al., 1998) the number of tandem 5-amino acid repeats in RR1 varies considerably 272 
between isolates with the M. hyopneumoniae J strain, possessing only nine tandem copies in 273 
contrast to the fifteen copies present in M. hyopneumoniae strain 232 (Wilton et al., 1998). 274 
However, adherence by M. hyopneumoniae to epithelial cilia is a multifactorial process involving 275 
an array of adhesins including those which lack RR1, and therefore the number of repeats in RR1 276 
as such may not be suitable as a virulence marker.  277 
It has been described that M. hyopneumoniae pathogenic strains were able to increase intracellular 278 
calcium concentrations in porcine ciliated epithelial cells. However, such increase was not 279 
observed in non-pathogenic M. hyopneumoniae and M. flocculare strains (Park et al., 2002). 280 
Additionally, M. hyopneumoniae strains characterized as highly virulent were able to induce 281 
higher cytoplasmic calcium concentrations in neutrophils, compared to low virulent ones, 282 
suggesting that signal transduction mechanisms in neutrophils are altered by virulent M. 283 
hyopneumoniae strains (Chen et al., 1992). 284 
Mycoplasma hyopneumoniae strain passaging in vitro or in vivo may alter the virulence quickly. 285 
DeBey and Ross (1994) showed that after 20 to 40 in vitro passages compared to only 1 or 2 286 
passage(s), M. hyopneumoniae strain 232 exhibited a lower capacity to induce ciliary damage. 287 
However, when the same previously passaged strain was passaged in gnotobiotic pigs in vivo, the 288 
strain was reversed to original virulence (DeBey and Ross, 1994). The reference strain J, 289 
commonly used in commercial vaccines, was originally a virulent and pathogenic strain causing 290 
mild pneumonia in sows. Nevertheless, after continued in vitro passaging, M. hyopneumoniae 291 
strain J lost its pathogenic capacity to adhere and to cause disease in pigs (Zielinski & Ross, 1993). 292 
In addition, a 23 kb region was also observed to be similar to a previously described Integrative 293 
Conjugal Element (ICE) of M. fermentans in the genetic material of M. hyopneumoniae strains 294 
7448 and 232, that was absent in J-strain (Pinto et al., 2007). This ICE is generally recognized to 295 
be involved in virulence in other Mycoplasma species. Therefore, the authors suggested that these 296 
putative ICE’s might also be implicated in the virulence of M. hyopneumoniae. Liu et al. (2013) 297 
not only detected this element in the virulent M. hyopneumoniae strain 168, but also in its 298 
attenuated variant.. Thus, the role of the ICE in the virulence of M. hyopneumoniae remains unclear 299 
and warrants further research (Maes et al., 2018). Using MLVA testing on lungs from slaughtered 300 
pigs, Charlebois et al. (2014) showed that M. hyopneumoniae strains lacking the detection of Locus 301 
1 protein exhibited significantly less severe lesions and lower numbers of bacteria. The gene 302 
amplified by this locus encodes for a hypothetical protein of 77078 kDa, and the authors suggested 303 
that this Locus 1 protein might be a potential virulence factor for M. hyopneumoniae. 304 
Mycoplasmas in general lack classical virulence factors like toxins. Nevertheless, the production 305 
of a community-acquired respiratory distress syndrome toxin was identified for M. pneumoniae, 306 
which has been shown to potentially contribute to this microorganism’s pathogenesis (Kannan et 307 
al., 2005; Medina et al., 2012). Therefore, the ability to detect the presence of unidentified toxins 308 
for other Mycoplasma species may be possible in the future. Ferrarini et al. (2018) recently 309 
demonstrated that pathogenic strains of M. hyopneumoniae are able to use glycerol as a carbon 310 
source thereby enabling the production of the toxic metabolite hydrogen peroxide. In a previous 311 
study, Ferrarini et al. (2016) showed that only M. hyopneumoniae, but not the commensal M. 312 
flocculare, was able to assimilate myo-inositol, and remained viable when this was the primary 313 
energy source. Therefore, mechanisms leading to virulence are complex and more research is 314 
needed to identify markers for virulence (Maes et al., 2018). 315 
2.3.3. Effect of the number of different strains on the severity of lung lesions 316 
Several M. hyopneumoniae strains can be detected in a herd, and even in one individual pig from 317 
bronchoalveolar lavage fluid or lung tissue (Nathues et al., 2011; Vranckx et al., 2011; Dos Santos 318 
et al., 2015; Michiels et al., 2017). Although some studies point in the direction that co-infection 319 
with more than one strain in a pig or batch of pigs might result in more severe lung lesions 320 
(Villarreal et al., 2009; Vranckx et al., 2011; Michiels et al., 2017), other studies did not detect 321 
such a relationship (Charlebois et al., 2014). Michiels et al. (2017) investigated the genetic 322 
diversity of M. hyopneumoniae strains in different successive batches of ten pig herds using 323 
Multiple-Locus Variable number tandem repeat Analysis (MLVA). Multivariable analyses 324 
accounting for the potential effect of risk factors for respiratory disease were performed to assess 325 
associations between the number of different Variable Number Tandem Repeats (VNTR) variants 326 
per batch, and lung lesions as outcome variables. Batches of slaughtered pigs with several M. 327 
hyopneumoniae strains showed a significantly higher prevalence and severity of Mycoplasma-like 328 
lung lesions at slaughter, implying that reducing the number of different strains may lead to less 329 
lung lesions at slaughter. The exact mechanisms leading to this phenomenon remain to be 330 
elucidated. 331 
2.3.4. Acquired antimicrobial resistance 332 
Antimicrobial susceptibility testing of M. hyopneumoniae is not routinely performed due to the 333 
fastidious isolation of the pathogen. In addition, established breakpoints are lacking for result 334 
interpretation and for identifying strains as sensitive or resistant. Mycoplasma hyopneumoniae is 335 
intrinsically resistant to antibiotics which interfere with the polymerization of cell wall precursors, 336 
such as beta-lactam antibiotics, and to polymyxins, 14-membered ring macrolides (such as 337 
oleandomycin and erythromycin), trimethoprim and sulfonamides. In-vitro, acquired resistance 338 
has been documented for tetracyclines, 15-membered ring macrolides (tulathromycin, 339 
gamithromycin), 16-membered ring macrolides (tylosin, tilmicosin), lincosamides (lincomycin) 340 
and fluoroquinolones (Vicca et al., 2004; Tavio et al., 2014; Klein et al., 2017; Felde et al., 2018).  341 
It was shown that mutations in the 23S rRNA gene were responsible for resistance to macrolides 342 
and lincosamides (Stakenborg et al., 2005). Isolates that were resistant against quinolones harbored 343 
mutations in the quinolone resistance-determining regions (QRDR) of gyrA, gyrB, parC or parE. 344 
In four out of five resistant isolates, there was only one-point mutation (C → A) in parC, resulting 345 
in an amino acid change from serine to tyrosine at position 80 (E. coli numbering). These isolates 346 
showed a minimum inhibitory concentration (MIC) of enrofloxacin of 0.5 μg/mL, while for 347 
sensitive isolates the MIC of enrofloxacin was ≤ 0.06 μg/mL. One resistant isolate had an extra 348 
mutation (C → T) in gyrA resulting in an amino acid change from alanine to valine at position 83 349 
(E. coli numbering), correlated with an increase in the MIC of enrofloxacin (> 1 μg/mL). Felde et 350 
al. (2018) showed that single nucleotide polymorphisms in parC correlated with a decrease in 351 
fluoroquinolone susceptibility.  No mutations resulting in an amino acid change were detected in 352 
the QRDR of the gyrB and parE genes of the selected isolates (Thongkamkoon et al., 2013; Felde 353 
et al., 2018). As summarized by Gautier-Bouchardon (2018), M. hyopneumoniae strains isolated 354 
from 2000 to 2016 showed higher in vitro MIC levels for tetracyclines, macrolides, lincosamides, 355 
and fluoroquinolones compared to those isolated prior to 2000.  356 
2.4. Genomic variability 357 
Through the employment of several molecular techniques, genomic variation has been evident in 358 
several M. hyopneumoniae strains and isolates at different geographic and population levels (Table 359 
2). The M. hyopneumoniae genome has been fully sequenced for six strains and has been described 360 
to be composed of 892,758-964,503 base pairs and contain a low G + C content of 28.4-28.6% 361 
(Minion et al., 2004; Vasconcelos et al., 2005; Liu et al., 2011; Siqueira et al., 2013; Han et al., 362 
2017). In addition, 679-692 predicted protein coding sequences have been described, in which 363 
approximately 44%, 38%, and 12% encode for hypothetically functional, conserved, and unique 364 
proteins, respectively (Minion et al., 2004; Vasconcelos et al., 2005; Liu et al., 2011; Siqueira et 365 
al., 2013; Han et al., 2017). Like other mycoplasmas, M. hyopneumoniae has the ability to modify 366 
gene and antigenic expression, which primarily occurs during DNA replication (Minion et al., 367 
2004). Within many lipoprotein and adhesion encoding genes, tandem repetitive regions of DNA, 368 
known as VNTRs are present and undergo phase variation, recombination, and slipped strand 369 
mispairing during replication, thus resulting in adherence and antigenic variation from 370 
modifications in cell surface structure (Razin et al., 1998; Rosengarten et al., 1999; Minion et al., 371 
2000; de Castro et al., 2006).  Differences in VNTR length of several adhesins and chromosomal 372 
restriction patterns have been described across M. hyopneumoniae strains and isolates using 373 
complete or individual gene sequencing (Hsu et al., 1998; Vasconcelos et al., 2005; Garza-Moreno 374 
et al., 2019), field inversion gel electrophoresis (Frey et al., 1992), and random amplified 375 
polymorphism DNA analysis (Artiushin et al., 1996).  376 
From a geographical standpoint, increased genomic heterogeneity has been demonstrated across 377 
M. hyopneumoniae isolates and strains originating from diverse regions (i.e. different countries) 378 
compared to those originating from a more localized region (Frey et al., 1992; Dos Santos et al., 379 
2015). The identification of potential drivers (e.g. temporal changes) for M. hyopneumoniae 380 
genomic heterogeneity across different geographical locations has not been investigated. Several 381 
M. hyopneumoniae VNTR types have been identified (Vranckx et al., 2011) within a country and 382 
individual state, suggesting a wide circulation of M. hyopneumoniae VNTR types in swine 383 
populations (Vranckx et al., 2011; Dos Santos et al., 2015; Takeuti et al., 2017). Among all VNTR 384 
types detected in different countries (i.e. United States, Mexico, Brazil, and Spain), a common M. 385 
hyopneumoniae VNTR type has not been detected (Dos Santos et al., 2015). In comparison, a 386 
similar circulation of VNTR types for M. pneumoniae has been shown across different countries 387 
(Dégrange et al., 2009). Furthermore, in swine dense geographical areas, multiple M. 388 
hyopneumoniae VNTR types has been identified in endemically infected herds and even in 389 
individual pigs (Vranckx et al., 2011; Nathues et al., 2011; Michiels et al., 2017). Greater 390 
homogeneity and/or identical M. hyopneumoniae VNTR types in herds that are of close 391 
geographical proximity, or herds that belong to the same production flow, has also been shown 392 
(Mayor et al., 2007; Charlebois et al., 2014; Pantoja et al., 2016; Takeuti et al., 2017; Rebaque et 393 
al., 2018). In all cases, one distinct M. hyopneumoniae VNTR type along with multiple clonal 394 
types (i.e. similar VNTR types) have been described. It could be hypothesized that the degree of 395 
M. hyopneumoniae genetic variability among herds might be influenced by herd management. 396 
However, the potential drivers and mechanisms of such heterogeneity have been poorly explored 397 
and defined. 398 
3. Molecular characterization methods of mycoplasmas  399 
3.1. Mycoplasma spp.   400 
With the advancement of molecular technology and more comprehensive knowledge of 401 
mycoplasmas, the repertoire of molecular diagnostics and characterization methods have expanded 402 
from nucleic acid amplification to the identification of single nucleotide polymorphism and 403 
variation in VNTR and house-keeping gene length and composition (Diaz & Winchell, 2016). The 404 
employment of sequencing and typing methods have allowed for a higher level of discrimination 405 
among strains and isolates to further understand Mycoplasma spp. epidemiology and pathogenesis 406 
(Diaz & Winchell, 2016).  407 
3.2. M. hyopneumoniae  408 
Several techniques have been standardized to molecularly characterize M. hyopneumoniae using 409 
nucleic acid amplification, including Amplified Fragment Length Polymorphism (AFLP; 410 
Kokotovic et al., 1999; Stakenborg et al., 2006), Restriction Amplified Polymorphic DNA analysis 411 
(RAPD; Artiushin & Minion, 1996; Vicca et al., 2003), Pulse-Field Gel Electrophoresis (PFGE; 412 
Stakenborg et al., 2006), Random Fragment Length Polymorphism (RFLP; Stakenborg et al., 413 
2006), and DNA Microarrays (Madsen et al., 2007). However, variations in reproducibility, 414 
feasibility, and discriminatory power exist among these molecular methods (Stakenborg et al., 415 
2006; Sibila et al., 2009). To provide further discrimination, Multiple-Locus Sequence Typing 416 
(MLST; Mayor et al., 2008), MLVA (Vranckx et al., 2011; Nathues et al., 2011; Dos Santos et al., 417 
2015; Tamiozzo et al., 2015), partial gene sequencing (Tsungda & Minion, 1998; Mayor et al., 418 
2007; Garza-Moreno et al., 2019), and complete genome sequencing (Minion et al., 2004; 419 
Vasconcelos et al., 2005; Liu et al., 2011; Siqueira et al., 2013; Han et al., 2017) have been recently 420 
employed.  While each molecular method has their strengths and disadvantages, it is important to 421 
consider the question at hand, resources available, and capabilities that each method can provide 422 
prior to the utilization of such techniques.  423 
Thus far, the utilization of molecular characterization methods for M. hyopneumoniae has been 424 
commonly employed in research settings. However, the application of M. hyopneumoniae genomic 425 
characterization in field investigations has increased in the United States to provide veterinarians 426 
additional insight related to the transmission and control of this microorganism. Although 427 
complete genome sequencing has been proposed as a highly descriptive and thorough method, the 428 
routine application of this technique may represent a more futuristic approach based on its current 429 
practicality and feasibility as it applies to disease investigations. Therefore, the utilization of typing 430 
methods (i.e. MLVA), complete or partial-gene sequencing for M. hyopneumoniae 431 
characterization has increased in veterinary diagnostic laboratories as the control and elimination 432 
of this microorganism is widely attempted worldwide (Maes et al., 2018).  433 
3.2.1 M. hyopneumoniae typing methods 434 
The most commonly employed genomic typing methods for M. hyopneumoniae are MLST and 435 
MLVA. The MLST assay has been utilized for many bacterial species and was standardized for 436 
the molecular characterization of M. hyopneumoniae by Mayor et al (2008). Several loci have been 437 
targeted, including putative and house-keeping genes (i.e. efp, metG, pgiB, recA, adk, rpoB, tpiA, 438 
gyrB, and gmk). As identified in Mycoplasma spp., house-keeping genes have been described to 439 
be highly conserved, resulting in limited variation among strains (Dumke et al., 2003). The MLVA 440 
assay is a typing method that identifies the number of VNTRs within surface proteins and has been 441 
employed for the molecular characterization of M. hyopneumoniae in Spain, Argentina, Belgium, 442 
United States, Mexico and Brazil (Table 3; de Castro et al., 2006; Vranckx et al., 2011; Dos Santos 443 
et al., 2015; Tamiozzo et al., 2015; Takeuti et al., 2017; Michiels et al., 2017). Several techniques 444 
have described the M. hyopneumoniae variability using different loci numbers (e.g. 2-4) and types 445 
(i.e. P97, P146, H1, H4, H5; Table 3). The targeted loci have been selected for their presumed 446 
bacterial adhesive capability to ciliated epithelium, presence of repetitive, tandem repeats, or high 447 
degree of variability (Vranckx et al., 2011; Dos Santos et al., 2015; Tamiozzo et al., 2015; Rebaque 448 
et al., 2018).  Currently, MLVA assay is commonly performed due to its high discriminatory 449 
power, reproducibility, and use of clinical samples has been widely implemented for 450 
epidemiological investigations (Vranckx et al., 2011; Dos Santos et al., 2015). Despite this, current 451 
discrepancies regarding the genomic characterization of M. hyopneumoniae and interpretation 452 
currently exist. Like other typing methods, MLVA evaluates few genomic areas. Therefore, other 453 
areas within the genome that may influence variability may be unrepresented.  454 
3.2.2 M. hyopneumoniae sequencing methods 455 
Genomic sequencing methods have been developed to evaluate the entire genome or individual 456 
genes of M. hyopneumoniae. To further explore how the genomic structure of M. hyopneumoniae 457 
can influence pathogenesis and host-pathogen interaction, complete genome sequencing has been 458 
attempted (Minion et al., 2004; Vasconcelos et al., 2005; Liu et al., 2011; Siqueira et al., 2013; 459 
Han et al., 2017). While this molecular technique offers descriptive and thorough information, the 460 
feasibility to routinely perform complete genome sequencing may be limited due to cost, difficulty 461 
of interpretation, computational requirements, and the need for sophisticated equipment. 462 
Therefore, complete or partial sequencing of individual M. hyopneumoniae genes has been 463 
attempted for the purpose of strain typing (Mayor et al., 2007; Felde et al., 2018). Due to the 464 
paralogous nature of P146 with P97, and the presence of distinct motifs and consensus regions (i.e. 465 
PQ, S, PS for locus P146), partial sequencing of the encoded gene Mhp-684 (3954 bp) has been 466 
previously described (Mayor et al., 2007; Bogema et al., 2012). Throughout the employment of 467 
sequencing methods, the number of VNTRs have also been evaluated for M. hyopneumoniae 468 
(Felde et al., 2018; Garza-Moreno et al., 2019). However, as well with MLVA, there is limited 469 
knowledge on the interpretation of sequencing methods and the insight gained from the 470 
comparison of molecular assays that evaluate nucleotide differences at the consensus or individual 471 
gene level. To provide further understanding, a comprehensive review of the M. hyopneumoniae 472 
genome is necessary to identify regions that can be utilized for classification, as well as for 473 
prevention and control efforts.  474 
4. Proposed terminology for the study of M. hyopneumoniae genomic variability 475 
To provide clarity on disease investigations, defining a commonality for M. hyopneumoniae 476 
genomic classification using MLVA is proposed based on current knowledge. One of the reasons 477 
why a genomic classification criterion for M. hyopneumoniae has not been previously established 478 
for MLVA is due to the fact that the agreement of a common technique and terminology has not 479 
been made. However, a systematic and scientific approach to genetically classify M. 480 
hyopneumoniae should be made in congruency to help promote and drive scientific knowledge 481 
advancement on this microorganism.   482 
Across the literature, different terms such as strains, variants, types, and typing profiles have been 483 
used to define M. hyopneumoniae strains according to the VNTRs obtained by different typing or 484 
sequencing methods. In this review, the term ‘VNTR types’ is suggested since the terminology 485 
‘strain’ is often defined as a pathogen that has been isolated and characterized and a ‘variant’ refers 486 
to any genomic modification of a pathogen. In addition, the term ‘VNTR types’ is proposed as it 487 
can be incorporated for MLVA and sequencing assays that are employed to evaluate the number 488 
of VNTRs within specific loci.   489 
Classification of determining a unique or different M. hyopneumoniae VNTR type compared to 490 
other types varies and continues to be arbitrary. Such variation across several MLVA techniques 491 
may be due to differences in the type and number of loci targeted as well as analytic method. For 492 
example, one method for classifying a unique M. hyopneumoniae VNTR type may be based on 493 
one tandem repeat difference in surface adhesin proteins (e.g. 16-17 to 17-17). In comparison, this 494 
minute difference in VNTR length might be perceived from a genomic modification, probably 495 
without biological significance and related to host-pathogen adaptations during evolutional 496 
pressures. Currently, the biological importance of variations in VNTR length and translation of 497 
repeat motifs remains unclear. Due to these reasons, the ability to make inferences from previously 498 
published literature to understand the genomic variability of M. hyopneumoniae becomes 499 
challenging, especially when different techniques are employed. Therefore, it is proposed that a 500 
minimum of two loci (i.e. P97 and P146) should be included in published literature papers. On the 501 
other hand, minimum spanning trees and unweighted pair group method with arithmetic mean 502 
(UPGMA) dendrograms have been employed to illustrate differences between VNTR types; 503 
however, the relationship and/or difference among types is not easily portrayed as each locus is 504 
unequally weighted. Therefore, the need to identify a bioinformatics tool that can portray 505 
differences between VNTR types in a systematic and numerical manner is highlighted. 506 
Furthermore, there is a need to create a database of M. hyopneumoniae VNTR types worldwide, 507 
with a curator and free access. In doing so, this knowledge can be applied towards the development 508 
of a genomic classification method for M. hyopneumoniae. 509 
5. Conclusions  510 
Mycoplasma hyopneumoniae variation across several strains and field isolates has been described 511 
at the antigenic, proteomic, transcriptomic, pathogenic, and genomic levels. This microorganism 512 
may undergo adaptations that may drive variation and differences between host-pathogen 513 
interactions. One approach to provide further insight on this topic is the molecular characterization 514 
of M. hyopneumoniae using genomic sequencing and typing methods, which has been commonly 515 
implemented in research and clinical investigations. However, the agreement of a shared 516 
terminology and classification for the various techniques, specifically MLVA, has not been 517 
described and thus causes discrepancies and the inability to make inferences across the literature. 518 
Therefore, current molecular trends for M. hyopneumoniae have been outlined and common 519 
terminology and classification based on VNTR types has been proposed. 520 
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